Ligand Pharmaceuticals Incorporated · NASDAQ:LGND
Aryeh Jason sold 2,111 Ligand Pharmaceuticals Incorporated shares (Form 4)
Traded Oct 30 to Nov 2, 2026 · Filed Nov 3, 2026
From Oct 30 to Nov 2, 2026, Aryeh Jason (Director) sold 2,111 Ligand Pharmaceuticals Incorporated shares at an average US$320.30 for US$676K, leaving 108,758 shares. Filed Nov 3, 2026 (Form 4).
- Sold
- 2,111 shares
- Price
- US$320.30 average (US$317.74 to US$320.49)
- Value
- US$676K
- Holding after
- 108,758 shares
- Trading plan
- No
- Role
- Director
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Oct 30, 2026 | Common Stock | Sale | 50 | US$317.74 | 110,819 | Direct |
| Oct 30, 2026 | Common Stock | Sale | 50 | US$318.23 | 110,769 | Direct |
| Oct 30, 2026 | Common Stock | Sale | 52 | US$320.24 | 110,717 | Direct |
| Oct 30, 2026 | Common Stock | Sale | 1,209 | US$320.42 | 109,508 | Direct |
| Oct 30, 2026 | Common Stock | Sale | 50 | US$320.49 | 109,458 | Direct |
| Nov 2, 2026 | Common Stock | Sale | 700 | US$320.43 | 108,758 | Direct |
Source
Download original · View original at SEC
Related
- Ligand Pharmaceuticals Incorporated
- Aryeh Jason
- Ligand Pharmaceuticals Incorporated shareholders
- Form 4 · Aryeh Jason · Nov 12, 2026
- Form 4 · Aryeh Jason · Nov 6, 2026
- Form 4 · Aryeh Jason · Jun 12, 2026
- Form 4 · Kozarich John W · Nov 16, 2026
- Form 4 · Zimmermann Martine · Nov 16, 2026
- Schedule 13G/A · Janus Henderson Group Ltd. · Nov 16, 2026
- Schedule 13G/A · Invesco Ltd. · Nov 10, 2026
- Form 4 · Reardon Andrew · Nov 4, 2026